Prospective investigation of immunotherapy-induced fatigue by rest and stress echocardiography. Read more about Prospective investigation of immunotherapy-induced fatigue by rest and stress echocardiography.
Rural and urban disparities based on zip code of residence: Analyses of 834 and 2,159 patients in NCCTG N9741 and CALGB 80405 (Alliance) trials respectively. Read more about Rural and urban disparities based on zip code of residence: Analyses of 834 and 2,159 patients in NCCTG N9741 and CALGB 80405 (Alliance) trials respectively.
Investigating macrophage function as a mechanism of resistance to daratumumab in relapsed refractory multiple myeloma patients. Read more about Investigating macrophage function as a mechanism of resistance to daratumumab in relapsed refractory multiple myeloma patients.
Phase I trial of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma. Read more about Phase I trial of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.
Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors. Read more about Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.
Correlation of tumor mutational burden (TMB) with molecular profiling and clinical characteristics in patients with bladder cancer. Read more about Correlation of tumor mutational burden (TMB) with molecular profiling and clinical characteristics in patients with bladder cancer.
Pazopanib (PZ) plus endocrine therapy as treatment for hormone resistant advanced breast cancer (ABC). Read more about Pazopanib (PZ) plus endocrine therapy as treatment for hormone resistant advanced breast cancer (ABC).
A phase Ib/II study of eribulin with cyclophosphamide (EC) in patients (pts) with advanced breast cancer (ABC). Read more about A phase Ib/II study of eribulin with cyclophosphamide (EC) in patients (pts) with advanced breast cancer (ABC).
A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression. Read more about A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.
Health plan expenditures young adults with newly-diagnosed Hodgkin lymphoma (HL) by care at NCI-designated comprehensive cancer centers (CCC) vs. other treatment sites (non-CCC). Read more about Health plan expenditures young adults with newly-diagnosed Hodgkin lymphoma (HL) by care at NCI-designated comprehensive cancer centers (CCC) vs. other treatment sites (non-CCC).
